Physician profile
Robert W Bartel
NPI 1164538203
$2,182.63
in general payments reported to CMS, 2019-2025
23 companies · $147 in 2025
The $147 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $334 · 2021: $473 · 2022: $186 · 2023: $325 · 2024: $103 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $486 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $485.95 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $478.82 | 2019-2025 | Ozempic |
| Glaxosmithkline, LLC. | $355.55 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $220.29 | 2022-2023 | Farxiga |
| Lilly USA, LLC | $174.55 | 2019-2023 | Mounjaro |
| Amgen INC. | $172.15 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $112.11 | 2019-2021 | |
| Abbvie INC. | $102.76 | 2021-2024 | Vraylar |
| Astellas Pharma US INC | $90.00 | 2024 | |
| Allergan, INC. | $72.04 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $57.57 | 2023 | Qelbree |
| Indivior INC. | $51.93 | 2019 | |
| Pfizer INC. | $49.00 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.77 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $44.34 | 2019-2021 | |
| Shire North American Group INC | $22.97 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $22.42 | 2025 | |
| Janssen Pharmaceuticals, INC | $19.21 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.45 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.01 | 2020 | |
| Acadia Pharmaceuticals INC | $15.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.87 | 2020 | |
| Orexo US, INC. | $14.74 | 2021 | |
| Corium, LLC | $10.71 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bartel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.